Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by First Citizens Bank & Trust Co.

First Citizens Bank & Trust Co. raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 16.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,704 shares of the biopharmaceutical company’s stock after buying an additional 681 shares during the period. First Citizens Bank & Trust Co.’s holdings in Halozyme Therapeutics were worth $225,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of HALO. Verdence Capital Advisors LLC raised its stake in Halozyme Therapeutics by 1.9% during the 3rd quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after acquiring an additional 252 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares during the last quarter. Juncture Wealth Strategies LLC lifted its holdings in shares of Halozyme Therapeutics by 3.6% during the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock worth $690,000 after purchasing an additional 415 shares during the period. Diversify Advisory Services LLC raised its position in Halozyme Therapeutics by 8.5% during the 3rd quarter. Diversify Advisory Services LLC now owns 5,331 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 418 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC lifted its stake in shares of Halozyme Therapeutics by 7.7% in the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 7,118 shares of the biopharmaceutical company’s stock worth $407,000 after acquiring an additional 507 shares during the period. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Up 0.3 %

Shares of NASDAQ HALO opened at $56.00 on Wednesday. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm’s 50-day moving average is $50.08 and its two-hundred day moving average is $54.27. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53. The company has a market capitalization of $7.12 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24.

Analyst Ratings Changes

Several research analysts recently issued reports on HALO shares. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company reduced their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. HC Wainwright upped their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, January 10th. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.40% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.